FPR1 and breast carcinoma: ANXA1 has been shown to bind to the FPRs, FPR1 and FPR2, thereby activating the PI3K/AKT pathway in breast cancer.[18] A human phosphokinase antibody array study indicated that ANXA1 activated AKT signaling and inhibited autophagy in nasopharyngeal carcinoma cells.[20] Additionally, ANXA1 upregulation resulted in AKT inhibitors and trastuzumab resistance through activation of the HER2/PI3K/mTOR pathway.[19] Hence, these findings suggest that ANXA1 activates the AKT pathway and may represent a promising therapeutic target to reverse drug resistance in cancer cells.